{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-031008","form_type":"8-K","ticker":"AQST","cik":"0001398733","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.889934+00:00","generated_at":"2026-05-17T12:59:35.508847+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aquestive secures $75M funding from RTW for Anaphylm launch, contingent on FDA approval","bullets":["$75M purchase price from RTW, subject to FDA approval of Anaphylm and refinancing of existing 13.5% senior notes.","Revenue share payments of 7.5%-1.0% of US net sales (9.5% if low sales) capped at $187.5M by 2035 or $225M thereafter.","Funding supports commercial launch; CEO says capital through 2027; Cantor Fitzgerald advised Aquestive.","RTW Managing Partner Roderick Wong: 'investment reflects belief in Anaphylm's commercial prospects.'"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-031008","json":"https://secwatch.observer/filing/0001140361-25-031008.json","markdown":"https://secwatch.observer/filing/0001140361-25-031008.md","text":"https://secwatch.observer/filing/0001140361-25-031008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1398733/000114036125031008/0001140361-25-031008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1398733/000114036125031008/ef20053941_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T12:59:35.508847+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}